Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019

– Post hoc analyses of LONHALA MAGNAIR evaluated lung function in
patients with common COPD comorbidities –

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion
Pharmaceuticals Inc. (Sunovion) will present data from its portfolio
of treatments for chronic obstructive pulmonary disease (COPD) at the
American Thoracic Society International Conference 2019 (ATS 2019),
taking place May 17-22, 2019 in Dallas, Texas.

“Several of Sunovion’s presentations at ATS 2019 focus on the importance
of comorbidities, including anxiety and depressive symptoms and
metabolic syndrome, on physiological and symptomatic responses in
patients with moderate-to-very severe COPD who participated in the
LONHALA MAGNAIR clinical program,” said Thomas H. Goodin, Ph.D., Senior
Director of Clinical Development at Sunovion. “COPD is a serious and
complex medical condition that affects millions of Americans. Patients
with COPD often present in the clinic with significant medical and
psychiatric comorbidities. Therefore, it is important to provide these
data from post hoc analyses to healthcare practitioners that evaluate
the effectiveness and tolerability of a COPD therapy in the presence of
other relevant medical conditions to help support individualized patient
care.”

Lonhala^® Magnair^® (glycopyrrolate) Inhalation
Solution (25 mcg twice daily) was the first nebulized long-acting
muscarinic antagonist (LAMA) approved for the treatment of COPD in the
U.S. LONHALA is administered by oral inhalation exclusively through the
MAGNAIR Nebulizer System, which uses eFlow^® technology
developed by PARI Pharma GmbH. The MAGNAIR Nebulizer System is a
virtually silent, portable, closed system nebulizer that is designed to
administer the medication in two to three minutes, as people breathe
normally. Sunovion received approval from the U.S. Food and Drug
Administration (FDA) for LONHALA MAGNAIR in December 2017, and it became
available to patients in April 2018.

Sunovion presentations at ATS 2019 include:

• Poster #P624: Improvement in Lung Function and Patient-Reported
  Outcomes in Patients with COPD with Comorbid Anxiety and Depression
  Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
  (Monday, May 20, 11:15 a.m. – 1:00 p.m. CDT, Area D, (Hall F, Level 2))
• Poster #P620: Effect of Metabolic Syndrome Status on Lung
  Function and Patient-Reported Outcomes in Patients with COPD Receiving
  Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies (Monday, May
  20, 11:15 a.m. – 1:00 p.m. CDT, Area D, (Hall F, Level 2))
• Poster #P621: Use of a Comorbidity Count to Assess the
  Prevalence of Comorbidities in the GOLDEN 3 and 4 Randomized Clinical
  Trials in Patients with Moderate-to-Very-Severe COPD (Monday, May 20,
  11:15 a.m. – 1:00 p.m. CDT, Area D, (Hall F, Level 2))
• Poster #P625: The Impact of Missing Spirometry Data in the
  GOLDEN 3 and 4 Studies of Patients with Moderate-to-Very-Severe COPD
  Treated with Nebulized Glycopyrrolate (Monday, May 20, 11:15 a.m. –
  1:00 p.m. CDT, Area D, (Hall F, Level 2))
• Poster #P623: Lung Function and Patient-reported Outcomes with
  Nebulized Glycopyrrolate in Patients with COPD by Baseline Rescue
  Medication Use in the Phase 3 GOLDEN 3 and 4 Studies (Monday, May 20,
  11:15 a.m. – 1:00 p.m. CDT, Area D, (Hall F, Level 2))
• Poster #P619: Effect of Gender on Lung Function and
  Patient-Reported Outcomes in Patients with COPD Receiving Nebulized
  Glycopyrrolate in the GOLDEN 3 and 4 Studies (Monday, May 20, 11:15
  a.m. – 1:00 p.m. CDT, Area D, (Hall F, Level 2))
• Poster #P815: Clinically Important Deterioration Among Patients
  with Chronic Obstructive Pulmonary Disease (COPD) Treated with
  Glycopyrrolate eFlow^® Closed System (CS) (Nebulized
  Glycopyrrolate) in Pooled Data from Two Randomized, Double Blind,
  Placebo-Controlled Studies (Tuesday, May 21, 11:15 a.m. – 1:00 p.m.
  CDT, Area F (Hall F, Level 2))
• Poster #P522: Overuse of Short-Acting Bronchodilators and the
  Risk of Exacerbation Among Patients with Chronic Obstructive Pulmonary
  Disease (COPD) Treated with Nebulized Short-Acting Bronchodilators
  (Wednesday, May 22, 1:30 p.m. – 3:30 p.m. CDT, Room D222-D224 (Level
  2))

Important Safety Information for LONHALA MAGNAIR (glycopyrrolate)
Inhalation Solution

INDICATION

LONHALA^® MAGNAIR^® (glycopyrrolate) is a medicine
called an anticholinergic. LONHALA MAGNAIR is used long term, twice each
day (morning and evening), for maintenance treatment of chronic
obstructive pulmonary disease (COPD), including chronic bronchitis
and/or emphysema.

IMPORTANT SAFETY INFORMATION

LONHALA MAGNAIR does not relieve sudden symptoms of COPD and should not
be used more than twice daily. Always have a short-acting beta₂-agonist
with you to treat sudden symptoms.

Do not use LONHALA MAGNAIR unless your health care provider has taught
you how to use the device and you understand how to use it correctly.
Use LONHALA MAGNAIR exactly as your health care provider tells you to
use it.

Do not use LONHALA MAGNAIR more often than is prescribed for you. Do not
stop using LONHALA MAGNAIR or other medicines to control or treat your
COPD unless told to do so by your health care provider because your
symptoms might get worse. Your health care provider will change your
medicines as needed.

Get emergency medical care if your breathing problems worsen quickly,
you need to use your rescue medication more often than usual, or your
rescue medication does not work as well to relieve your symptoms.

Do not use LONHALA MAGNAIR if you are allergic to glycopyrrolate or to
any of the ingredients in LONHALA MAGNAIR. Ask your health care provider
if you are not sure.

Tell your health care provider about all of your health conditions,
including if you:

• have kidney problems
• have eye problems such as glaucoma
• have prostate or bladder problems, or problems passing urine
• have any other medical conditions
• are pregnant or plan to become pregnant
• are breastfeeding or plan to breastfeed
• are allergic to LONHALA MAGNAIR or any of its ingredients, or to any
  other medicines or food products

Tell your health care provider about all the medicines you take,
including prescription medicines, over-the-counter medicines, vitamins,
and herbal supplements. LONHALA MAGNAIR and certain other medicines may
interact with each other. This may cause serious side effects.

Especially tell your health care provider if you take anticholinergics
(including umeclidinium, tiotropium, ipratropium, aclidinium,
glycopyrrolate).

LONHALA MAGNAIR can cause serious side effects, including:

• sudden shortness of breath (that may be life-threatening) immediately
  after use of LONHALA MAGNAIR
• serious allergic reactions, including: rash; hives; swelling of the
  tongue, lips, and face; and difficulty breathing or swallowing. Call
  your health care provider or get emergency medical care if you get any
  symptoms of a serious allergic reaction
• new or worsened eye problems, including acute narrow-angle glaucoma
  (symptoms may include eye pain or discomfort, blurred vision, red
  eyes, nausea or vomiting, seeing halos or bright colors around lights)
• new or worsened urinary retention (symptoms may include difficulty
  urinating, urinating frequently, painful urination, urination in a
  weak stream or drips)

Common side effects of LONHALA MAGNAIR include shortness of breath and
urinary tract infection.

These are not all of the possible side effects with LONHALA MAGNAIR.
Tell your health care provider about any side effect that bothers you or
that does not go away.

LONHALA solution is for oral inhalation only and should not be injected
or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088.

This information is not comprehensive.

How to get more information:

• Talk to your health care provider
• Visit www.lonhalamagnair.com
  to obtain the FDA-approved product labeling
• Call 1-888-394-7377

For additional information, please see full Prescribing
Information and Patient Information for LONHALA MAGNAIR at www.LonhalaMagnair.com.

About Long-Acting Muscarinic Antagonists (LAMAs)
A
long-acting muscarinic antagonist (LAMA) is a type of long-acting
bronchodilator, along with long-acting beta₂-agonists
(LABAs). According to the GOLD 2018 report, these bronchodilators are
currently the first-line standard of care maintenance therapy for
symptomatic individuals with COPD and help the muscles around the
airways in lungs stay relaxed to prevent symptoms such as wheezing,
coughing, chest tightness and shortness of breath.^1,2 LAMAs
are widely used and an important therapeutic approach for people with
COPD.

About COPD
Chronic obstructive pulmonary disease (COPD) is a
common, preventable and treatable disease that is characterized by
persistent respiratory symptoms and airflow limitation that is due to
airway and/or lung abnormalities usually caused by significant exposure
to toxic particles or gases. The main risk factor for COPD is tobacco
smoking, but other environmental exposures may contribute.² Approximately
15.7 million adults in the U.S. report that they have been diagnosed
with COPD.¹ It is estimated that several million more adults
have undiagnosed COPD.² COPD is responsible for over 120,000
deaths per year, making it the fourth leading cause of death in the U.S.¹
COPD develops slowly and the symptoms often worsen over time,
potentially limiting the ability to perform routine activities.²
Symptoms of COPD include coughing, wheezing, shortness of breath, excess
production of mucus in the lungs, the inability to breathe deeply and
the feeling of being unable to breathe.¹ The symptoms of COPD
can be most severe during the night and early morning.³ Morning
symptoms can be associated with limitation of activities during the day,
impaired health status and increased risk of exacerbation.⁴
Night-time symptoms disturb sleep, reduce sleep quality and, in the long
term, may be associated with development or worsening of cardiovascular
diseases, cognition, depression and increased mortality.⁵

About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a
global biopharmaceutical company focused on the innovative application
of science and medicine to help people with serious medical conditions.
Sunovion’s vision is to lead the way to a healthier world. The company’s
spirit of innovation is driven by the conviction that scientific
excellence paired with meaningful advocacy and relevant education can
improve lives. With patients at the center of everything it does,
Sunovion has charted new paths to life-transforming treatments that
reflect ongoing investments in research and development and an
unwavering commitment to support people with psychiatric, neurological
and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect,
wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion
Pharmaceuticals Europe Ltd., based in London, England, and Sunovion
Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are
wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.
Additional information can be found on the company’s websites: www.sunovion.com,
www.sunovion.eu and www.sunovion.ca.
Connect with Sunovion on Twitter,
LinkedIn,
Facebook
and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon
Pharma is among the top-ten listed pharmaceutical companies in Japan
operating globally in major pharmaceutical markets, including Japan, the
United States, China and the European Union. Sumitomo Dainippon Pharma
aims to create innovative pharmaceutical products in the Psychiatry and
Neurology area and the Oncology area, which have been designated as the
focus therapeutic areas. Sumitomo Dainippon Pharma is based on the
merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about
6,200 employees worldwide. Additional information about Sumitomo
Dainippon Pharma is available through its corporate website at www.ds-pharma.com.

LONHALA is a registered trademark of Sunovion Pharmaceuticals Inc.
MAGNAIR is a registered trademark of PARI Pharma GmbH, used under
license. eFlow is a registered trademark of PARI Pharma GmbH.

SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co. Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon
Pharma Co., Ltd.
© 2019 Sunovion Pharmaceuticals
Inc. All rights reserved.

For a copy of this release, visit Sunovion’s website at www.sunovion.com

References
¹ National Heart, Lung and Blood
Institute. (2013). “What Are the Signs and Symptoms of COPD?” Retrieved
from https://www.nhlbi.nih.gov/health/health-topics/topics/copd/signs.
²
National Heart, Lung, and Blood Institute. “What is COPD?” Available at: http://www.nhlbi.nih.gov/health/educational/copd/what-is-copd/index.htm.
Accessed: March 2, 2016.
³ Partridge MR, Karlsson N,
Small IR. Patient insight into the impact of chronic obstructive
pulmonary disease in the morning: an internet survey. Curr Med Res Opin.
2009;25:2043–8.
⁴ Roche N, Small M, Broomfield S,
Higgins V, Pollard R. Real world COPD: association of morning symptoms
with clinical and patient reported outcomes. COPD. 2013;10:679–86.
⁵
Agusti A, Hedner J, Marin JM, Barbé F, Cazzola M, Rennard S. Night-time
symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183–94.

Contacts

Kirsten Fallon
Senior Manager, Portfolio Communications
Sunovion
Pharmaceuticals Inc.
774-369-7116
[email protected]